Interim Financial Statements (Un-audited)

For the period July 2025-March 2026

Beximco Pharmaceuticals PLC.

Beximco Pharmaceuticals PLC. and its Subsidiaries

Financial Statements (Un-audited)

For the period July 2025-March 2026

Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of financial position (Un-audited)
As at March 31, 2026

Taka '000

	Notes	March 31, 2026	June 30, 2025
ASSETS			
Non-current assets		**50,664,655**	**49,461,242**
Property, plant and equipment	4	44,822,991	43,541,872
Right-of-use assets		423,012	485,613
Intangible assets		4,689,328	4,694,134
Deferred tax asset		33,780	44,079
Goodwill	5	674,570	674,570
Other investments	6	20,974	20,974
Current assets		**28,066,596**	**23,786,005**
Inventories	7	14,225,662	13,586,476
Spares and supplies		966,481	799,644
Trade and other receivables		3,768,406	3,628,788
Loans, advances, deposits and prepayments	8	3,528,252	2,814,492
Advance income tax		400,152	356,508
Short term investment		950,000	900,000
Cash and cash equivalents	9	4,227,643	1,700,097
TOTAL ASSETS		**78,731,251**	**73,247,247**
EQUITY AND LIABILITIES			
Equity attributable to the owners of the company		**60,048,483**	**53,107,137**
Share capital		4,461,121	4,461,121
Share premium		5,269,475	5,269,475
Excess of issue price over face value of GDRs		1,689,637	1,689,637
Capital reserve on merger		294,951	294,951
Revaluation surplus		1,131,583	1,133,870
Unrealized gain/(loss)		18,149	18,149
Retained earnings		47,183,567	40,239,934
Non-controlling interest		**4,047,682**	**3,977,499**
TOTAL EQUITY		**64,096,165**	**57,084,636**
Non-current liabilities		**7,831,707**	**7,769,471**
Long term borrowings-net of current maturity	10A	1,298,330	1,503,595
Liability for gratuity, pension and WPPF		3,951,697	3,690,096
Deferred tax liability		2,581,680	2,575,780
Current liabilities		**6,803,379**	**8,393,140**
Short term borrowings		973,567	2,025,394
Long term borrowings-current maturity	10B	891,550	1,436,752
Trade and other payables		2,124,152	2,925,994
Accrued expenses		1,394,433	1,174,096
Dividend payable		137,932	302,272
Income tax payable		1,281,745	528,632
TOTAL LIABILITIES		**14,635,086**	**16,162,611**
TOTAL EQUITY AND LIABILITIES		**78,731,251**	**73,247,247**

Osman Kaiser Chowdhury	Prof. Mamtaz Uddin Ahmed	Iqbal Ahmed	Mohammad Ali Nawaz	Mohammad Asad Ullah, FCS
Director	Independent Director	Managing Director	Chief Financial Officer	Executive Director & Company Secretary

Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of profit or loss and other comprehensive income (Un-audited)
For the period July 2025-March 2026

Taka '000

	Notes	July 2025-March 2026	July 2024-March 2025	January-March 2026	January-March 2025
Net revenue		**41,427,963**	**36,621,960**	**13,627,807**	**12,608,553**
Cost of goods sold	11	(21,118,060)	(19,822,775)	(6,931,325)	(6,787,928)
Gross profit		**20,309,903**	**16,799,185**	**6,696,482**	**5,820,625**
Operating expenses		**(10,737,944)**	**(9,288,133)**	**(3,687,910)**	**(3,397,216)**
General and administrative expenses	12	(1,133,559)	(1,026,632)	(381,590)	(338,255)
Selling, marketing and distribution expenses	13	(9,604,385)	(8,261,501)	(3,306,320)	(3,058,961)
Profit from operations		**9,571,959**	**7,511,052**	**3,008,572**	**2,423,409**
Other income	14	566,312	481,900	193,267	255,344
Finance cost		(519,609)	(802,608)	(146,061)	(314,630)
Profit before tax and WPPF		**9,618,662**	**7,190,344**	**3,055,778**	**2,364,123**
Contribution to WPPF		(467,208)	(351,606)	(148,998)	(116,347)
Profit before tax		**9,151,454**	**6,838,738**	**2,906,780**	**2,247,776**
Income tax expenses		**(2,102,822)**	**(1,577,731)**	**(652,351)**	**(521,780)**
Current tax		(2,085,959)	(1,580,974)	(651,677)	(517,572)
Deferred tax	15	(16,863)	3,243	(674)	(4,208)
Profit after tax		**7,048,632**	**5,261,007**	**2,254,429**	**1,725,996**
Profit/(loss) attributable to:					
Owners of the Company		6,940,682	5,231,738	2,219,926	1,721,356
Non-controlling interest		107,950	29,269	34,503	4,640
		7,048,632	**5,261,007**	**2,254,429**	**1,725,996**
Other comprehensive income/(loss)		-	1	-	-
Total comprehensive income		**7,048,632**	**5,261,008**	**2,254,429**	**1,725,996**
Total comprehensive income attributable to:					
Owners of the Company		6,940,682	5,231,739	2,219,926	1,721,356
Non-controlling interest		107,950	29,269	34,503	4,640
		7,048,632	**5,261,008**	**2,254,429**	**1,725,996**
Earnings per share (EPS)		**15.56**	**11.73**	**4.98**	**3.86**
Number of shares	Nos.	446,112,089	446,112,089	446,112,089	446,112,089

Osman Kaiser Chowdhury	Prof. Mamtaz Uddin Ahmed	Iqbal Ahmed	Mohammad Ali Nawaz	Mohammad Asad Ullah, FCS
Director	Independent Director	Managing Director	Chief Financial Officer	Executive Director & Company Secretary

Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of changes in equity (Un-audited)
For the period July 2025-March 2026

For the period July 2025-March 2026

Taka '000

	Share capital	Share premium	Excess of issue price over face value of GDRs	Capital reserve on merger	Revaluation surplus	Unrealized gain/(loss)	Retained earnings	Equity attributable to owners of the company	Non-controlling interest	Total equity
Balance as on July 01, 2025	**4,461,121**	**5,269,475**	**1,689,637**	**294,951**	**1,133,870**	**18,149**	**40,239,934**	**53,107,137**	**3,977,499**	**57,084,636**
Total comprehensive income:										
Profit/(loss) for the period	-	-	-	-	-	-	6,940,682	6,940,682	107,950	7,048,632
Other comprehensive income/(loss)	-	-	-	-	-	-	-	-	-	-
Transactions with the shareholders:										
Cash dividend	-	-	-	-	-	-	-	-	(37,767)	(37,767)
Others:										
Adjustment for depreciation on revalued assets	-	-	-	-	(2,951)	-	2,951	-	-	-
Adjustment for deferred tax on revalued assets	-	-	-	-	664	-	-	664	-	664
Balance as on March 31, 2026	**4,461,121**	**5,269,475**	**1,689,637**	**294,951**	**1,131,583**	**18,149**	**47,183,567**	**60,048,483**	**4,047,682**	**64,096,165**
Number of shares								446,112,089		
Net asset value (NAV) per share								**Tk. 134.60**		

For the period July 2024-March 2025

	Share capital	Share premium	Excess of issue price over face value of GDRs	Capital reserve on merger	Revaluation surplus	Unrealized gain/(loss)	Retained earnings	Equity attributable to owners of the company	Non-controlling interest	Total equity
Balance as on July 01, 2024	**4,461,121**	**5,269,475**	**1,689,637**	**294,951**	**1,137,306**	**18,148**	**35,079,327**	**47,949,965**	**3,952,938**	**51,902,903**
Total comprehensive income:										
Profit/(loss) for the period	-	-	-	-	-	-	5,231,738	5,231,738	29,269	5,261,007
Other comprehensive income/(loss)	-	-	-	-	-	1	-	1	-	1
Transactions with the shareholders:										
Cash dividend	-	-	-	-	-	-	(1,784,448)	(1,784,448)	(33,687)	(1,818,135)
Others:										
Adjustment for depreciation on revalued assets	-	-	-	-	(3,325)	-	3,325	-	-	-
Adjustment for deferred tax on revalued assets	-	-	-	-	748	-	-	748	-	748
Balance as on March 31, 2025	**4,461,121**	**5,269,475**	**1,689,637**	**294,951**	**1,134,729**	**18,149**	**38,529,942**	**51,398,004**	**3,948,520**	**55,346,524**
Number of shares								446,112,089		
Net asset value (NAV) per share								**Tk. 115.21**		

Osman Kaiser Chowdhury	**Prof. Mamtaz Uddin Ahmed**	**Iqbal Ahmed**	**Mohammad Ali Nawaz**	**Mohammad Asad Ullah, FCS**
Director	Independent Director	Managing Director	Chief Financial Officer	Executive Director & Company Secretary

Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of cash flows (Un-audited)
For the period July 2025-March 2026

Taka '000

	Notes	July 2025-March 2026	July 2024-March 2025
Cash flows from operating activities			
Cash receipts from customers and others		41,636,365	36,394,207
Cash paid to suppliers and employees		(32,436,664)	(30,100,181)
Cash generated from operations		**9,199,701**	**6,294,026**
Interest paid		(531,937)	(769,431)
Interest received		174,786	18,479
Income tax paid		(1,376,492)	(1,322,242)
Net cash generated from operating activities	**16**	**7,466,058**	**4,220,832**
Cash flows from investing activities			
Acquisition of property, plant and equipment		(2,664,525)	(2,220,342)
Intangible assets		(282,825)	(164,411)
Disposal of property, plant and equipment		11,353	40,123
Disposal of intangible assets		18,255	-
Dividend received		1,256	975
Short term investment		(50,000)	(700,000)
Net cash used in investing activities		**(2,966,486)**	**(3,043,655)**
Cash flows from financing activities			
Net increase/(decrease) in long term borrowings		(717,564)	47,161
Net increase/(decrease) in short term borrowings		(1,051,826)	1,390,117
Dividend paid		(202,106)	(1,593,640)
Net cash from/(used in) financing activities		**(1,971,496)**	**(156,362)**
Increase/(decrease) in cash and cash equivalents		**2,528,076**	**1,020,815**
Opening cash and cash equivalents		1,700,097	854,106
Effect of exchange rate changes on cash and cash equivalents		(530)	8,179
Closing cash and cash equivalents	**9**	**4,227,643**	**1,883,100**
Net operating cash flows per share		**16.74**	**9.46**
Number of shares		446,112,089	446,112,089

Osman Kaiser Chowdhury	Prof. Mamtaz Uddin Ahmed	Iqbal Ahmed	Mohammad Ali Nawaz	Mohammad Asad Ullah, FCS
Director	Independent Director	Managing Director	Chief Financial Officer	Executive Director & Company Secretary

Beximco Pharmaceuticals PLC. and its Subsidiaries
Selected notes to the financial statements (Un-audited)
For the period July 2025-March 2026

1 Reporting entity

1.1 About the Company

Beximco Pharmaceuticals PLC. (Beximco Pharma/BPP/the Company) is a public limited company incorporated in Bangladesh in 1976. It is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). Company's shares were first listed on the Dhaka Stock Exchange in 1985 and subsequently on the Chittagong Stock Exchange in 1995. In 2005, BPP acquired Beximco Infusions Ltd., a publicly listed company specializing in the production and marketing of intravenous fluids. To expand its global presence, BPP issued Global Depository Receipts (GDRs) and secured a listing on the Alternative Investment Market (AIM) of the London Stock Exchange. In 2018, BPP acquired 85.22% shares of Nuvista Pharma PLC. (Nuvista Pharma/NPP) – an unlisted pharmaceutical company in Bangladesh specializing in hormones and steroid drugs. In October 2021, BPP acquired majority stake (54.6%) in Sanofi Bangladesh Limited from Sanofi Group represented through May & Baker Limited and Fisons Limited. Sanofi Bangladesh Limited was subsequently renamed as Synovia Pharma PLC. (Synovia Pharma/SPP). Bangladesh Government holds 45.4% shares of the company represented through the Bangladesh Chemical Industries Corporation (20%) and the Ministry of Industries (25.4%). SPP, like Nuvista Pharma, is an unlisted pharmaceutical company operating in Bangladesh. Shares of Beximco Pharma are traded on the Dhaka and Chittagong Stock Exchanges within Bangladesh, while its GDRs are traded on the AIM of the London Stock Exchange.

The corporate headquarters of Beximco Pharma is based in Dhaka. The industrial units are located at Tongi and Kaliakoir of Gazipur district–vicinities close to the capital city Dhaka. The manufacturing facilities of the Company are certified by leading global regulatory authorities including United States Food and Drug Administration (USFDA).

1.2 The Subsidiaries

Nuvista Pharma PLC. (NPP)

Nuvista Pharma PLC., formerly Organon (Bangladesh) Ltd., was a subsidiary of Netherlands based Organon International. The Company has been operating in Bangladesh since 1964, with a local manufacturing facility at Tongi, Dhaka. Following the divestment of Organon's equity to the local management in 2006, the company was renamed as Nuvista Pharma. In 2018, Beximco Pharma acquired majority shareholdings in Nuvista Pharma and thus it became the immediate and ultimate parent of the company.

Synovia Pharma PLC. (SPP)

Synovia Pharma PLC. (formerly Sanofi Bangladesh Limited) had been a part of Sanofi S.A., a global biopharmaceutical company focused on human health. The company has been operating in Bangladesh since 1958. Following series of mergers, it was renamed as Sanofi Bangladesh Limited in 2013 before being acquired by Beximco Pharma in 2021 and subsequently renamed as Synovia Pharma PLC.

Beximco Pharma API Limited (BPAL)

Beximco Pharma API Limited was formed with an intend to set up a facility at API Industrial Park to manufacture Active Pharmaceutical Ingredients (APIs) for domestic and international markets. It is a private limited company with a paid up capital of Taka 20 million divided into 2 million shares of Taka 10 each, fully held by BPP excepting 10 shares. The company is still in the initial phase of establishment.

1.3 Nature of business

Beximco Pharma is engaged in manufacturing and marketing of generic pharmaceuticals formulation products covering a wide range of therapeutic categories. It offers products in different dosage forms including Solid, Liquid, Cream and Ointment, Suppositories, Metered Dose Inhaler, Dry Powder Inhaler, Nasal Spray, Sterile, Lyophilized Injectable and Large Volume Intravenous Fluids. Besides formulation products, BPP also manufactures Active Pharmaceutical Ingredients (APIs) and renders contract manufacturing services to other companies. Products of the Company are sold in domestic and international markets.

NPP produces various pharmaceutical products including oral contraceptives, hormone, steroid, anti-histamine, anti-fibrinolytic, anti-infective, gastrointestinal, musculoskeletal, respiratory, vitamin & mineral supplement and women's health products which are sold predominantly in the domestic and international market.

SPP produces generic pharmaceutical products and has a strong presence in cardiology, diabetes, oncology, dermatology and CNS. It also imports certain global brands of Sanofi including vaccines, insulins and chemotherapy drugs for sale in Bangladesh market. SPP produces approximately 100 branded generic products predominantly for the local market.

NPP and SPP also provide contract manufacturing services.

2. Basis of preparation of financial statements

These interim financial statements should be read in conjunction with the financial statements for the year ended June 30, 2025 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information.

The accounting policies used are consistent with those used in the annual financial statements. These financial statements have been prepared in a condensed form with selected notes following IAS 34: Interim Financial Reporting. The presentation of the interim financial statements is consistent with the annual financial statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the annual financial statements. The preparation of the interim financial statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the interim financial statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the interim financial statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

The financial statements are prepared and presented in Bangladesh Currency (Taka), which is the Company's functional currency. All financial information presented has been rounded off to the nearest thousand Taka except where indicated otherwise.

3. Significant Accounting Policies

3.1 Basis of consolidation

The financial statements of the subsidiaries have been consolidated with those of Beximco Pharmaceuticals PLC. in accordance with IFRS 10: Consolidated Financial Statements. The Company holds 85.2% and 54.6% shares of Nuvista Pharma PLC. and Synovia Pharma PLC, respectively. These ownership interests are adequate enough to establish control over the companies and thus BPP meets the conditions as stated in IFRS 10: Consolidated Financial Statements to consider NPP and SPP as subsidiaries. Beximco Pharma API Limited is fully owned by BPP and therefore, meets the conditions stated in IFRS 10: Consolidated Financial Statements to consider it as a subsidiary.

3.2 Inter-company transactions

Assets, liabilities, equity, income, expenses and cash flows arising out of transactions between the Company and its subsidiaries have been eliminated in full in the consolidated financial statements.

3.3 Non-controlling interests (NCIs)

Non-controlling interests (NCIs) at the date of acquisition have been measured at fair value of the net assets of the acquired companies in proportion to the shares held by the non-controlling shareholders. Profit or loss and other comprehensive income subsequent to the acquisitions have been allocated to the Owners of the Company and the NCIs in proportion to their respective shares and disclosed in the financial statements.

3.4 Valuation of goodwill

Goodwill has been determined in accordance with IFRS 3: Business Combination. This represents the excess of the aggregate of Purchase Consideration and the acquisition-date fair value of NCI's share in the identifiable net assets over the acquisition-date fair value of the identifiable net assets of the subsidiary.

3.5 Amortization of intangible assets

Fair value of identifiable intangible assets of subsidiaries at acquisition are amortized over a period of 25 years. Other intangible assets are amortized over their estimated useful period.

3.6 Investment in associates

Investment in Associates has been accounted for using the Equity method as per IAS 28: Investment in Associates and Joint Ventures. This represents value of 3,900,000 Ordinary Shares of Malaysian Ringgit (RM) 1 each issued to Beximco Pharmaceuticals PLC. by BioCare Manufacturing Sdn Bhd ("BioCare"), Malaysia. Beximco Pharmaceuticals Ltd. was issued 30% of the equity share of the Malaysian based company for providing technical support to set up a manufacturing facility to produce specialized pharmaceutical products in Malaysia. BioCare is considered to be an associate of BPP as per IAS 28: Investment in Associates and Joint Ventures.

Taka '000

		March 31, 2026	June 30, 2025
4.	**Property, plant and equipment**		
	Land	7,892,408	7,892,408
	Building and other constructions	17,058,096	16,988,099
	Plant and machinery	31,101,947	30,942,189
	Furniture and fixtures	1,115,878	1,068,138
	Transport and vehicle	1,371,381	1,241,587
	Office equipment	1,249,453	1,167,411
		59,789,163	**59,299,832**
	Less: Accumulated depreciation	(20,273,615)	(19,050,804)
	Net book value	**39,515,548**	**40,249,028**
	Capital work in progress	5,307,443	3,292,844
	Carrying value	**44,822,991**	**43,541,872**
5.	**Goodwill**		
	Nuvista Pharma PLC.	546,691	546,691
	Synovia Pharma PLC.	127,879	127,879
		674,570	**674,570**
6.	**Other investments**		
	Bangladesh Export Import Company PLC.	19,405	19,405
	Central Depository Bangladesh Ltd. (CDBL)	1,569	1,569
		20,974	**20,974**
7.	**Inventories**		
	Finished goods	3,019,013	2,857,233
	Raw and packing materials (including work in process, laboratory chemicals, R&D materials and material in transit)	11,078,655	10,620,058
	Physician sample	127,994	109,185
		14,225,662	**13,586,476**
8.	**Loans, advances, deposits and prepayments**		
	Clearing and forwarding	188,882	130,685
	VAT	775,719	646,507
	Security deposit & earnest money	222,029	207,432
	Lease deposit	1,477	1,477
	Advance for expenses including capital expenditure	874,809	598,786
	Bank guarantee margin	54,792	26,215
	Advance against salary	70,733	87,965
	Vehicle advance	319,141	278,318
	Raw & packing material	366,284	376,043
	Overseas liaison office	47,812	43,366
	Others	606,574	417,698
		3,528,252	**2,814,492**

Taka '000

		March 31, 2026	June 30, 2025
9.	**Cash and cash equivalents**		
	a. Cash in hand (including imprest cash)	624,091	381,426
	b. Cash at bank		
	Current & FC account	3,603,552	1,318,671
		4,227,643	**1,700,097**
10.	**Long term borrowings**		
	A. Net of current maturity		
	Project loan-ODDO BHF SE, Frankfurt, Germany	1,089,951	1,202,080
	Lease liability	208,379	301,515
		1,298,330	**1,503,595**
	B. Current maturity		
	Project loan-ODDO BHF SE, Frankfurt, Germany	526,772	300,520
	Term loan-Agrani Bank PLC.	274,391	1,017,850
	Lease liability	90,387	118,382
		891,550	**1,436,752**

		For the period July 2025-March 2026	For the period July 2024-March 2025
11.	**Cost of goods sold**		
	Work-in-process (opening)	1,480,666	1,301,205
	Materials consumed	15,271,878	14,809,506
	Factory overhead	5,288,391	4,984,743
	Total manufacturing cost	**22,040,935**	**21,095,454**
	Work-in-process (closing)	(1,276,515)	(1,344,105)
	Cost of goods manufactured	**20,764,420**	**19,751,349**
	Finished goods (opening)	2,857,234	2,785,997
	Purchase (imported and processed)	830,225	699,223
	Finished goods available	**24,451,879**	**23,236,569**
	Cost of physician sample transferred to sample stock	(314,806)	(290,416)
	Finished goods (closing)	(3,019,013)	(3,123,378)
		21,118,060	**19,822,775**

Taka '000

		For the period July 2025- March 2026	For the period July 2024- March 2025
12.	**General and administrative expenses**		
	Salaries and allowances	585,385	516,032
	Repairs and maintenance	70,290	79,877
	Travelling and conveyance	37,996	33,649
	Company secretarial, regulatory fee and AGM expense	39,628	35,146
	Depreciation	85,342	34,613
	Security expenses	68,069	35,900
	Other expenses	246,849	291,415
		1,133,559	**1,026,632**
13.	**Selling, marketing and distribution expenses**		
	Salaries and allowances	3,586,394	3,182,996
	Travelling and conveyance	1,010,099	822,059
	Market research and new products	46,202	41,071
	Sample expense	444,471	398,830
	Literature and newsletter	375,279	319,769
	Events, programs and campaign	580,945	467,007
	Brand development	223,599	165,895
	Sales promotion expenses	226,625	196,483
	Distribution commission	1,032,008	641,328
	Delivery expense	478,505	472,507
	Depreciation and amortization	368,323	314,797
	Export insurance, freight and C&F expenses	119,159	228,806
	Security expenses	34,945	32,301
	Bad debts	14,129	5,671
	Other expenses	1,063,702	971,981
		9,604,385	**8,261,501**
14.	**Other income**		
	Interest income	148,480	52,264
	Cash incentive on export	166,770	144,048
	Dividend income	1,256	1,142
	Royalty	200,963	196,621
	Exchange rate fluctuation gain/(loss)	32,958	79,593
	Profit/(loss) on sale of fixed assets	13,965	5,533
	Miscellaneous income	1,920	2,699
		566,312	**481,900**

Taka '000

		For the period July 2025-March 2026	For the period July 2024-March 2025
15.	**Deferred tax**		
	Deferred tax is arrived at as follows :		
	i. Beximco Pharma		
	Property, plant & equipment (difference in book value & tax base)	13,460,630	13,182,005
	Deferred liability (gratuity)	(1,836,470)	(1,872,784)
	Lease liability-(office rent)	(165,909)	-
	Provision for bad debts	(33,144)	(19,015)
	Temporary difference	**11,425,107**	**11,290,206**
	Tax rate	22.5%	22.5%
	Deferred tax liability at end of the period	2,570,649	2,540,296
	Deferred tax liability at beginning of the period	2,555,502	2,538,059
	Change in deferred tax liability	(15,147)	(2,237)
	Deferred tax on revaluation surplus	(664)	(748)
	Deferred tax charged to profit or loss and other comprehensive income	**(15,811)**	**(2,985)**
	ii. Nuvista Pharma		
	Property, plant & equipment (difference in book value & tax base)	307,815	348,163
	Deferred liability (gratuity)	(264,030)	(256,465)
	Provision for bad debts	(3,671)	(3,497)
	Temporary difference	**40,114**	**88,201**
	Tax rate	27.5%	25.0%
	Deferred tax liability at end of the period	11,031	22,050
	Deferred tax liability at beginning of the period	20,278	36,523
	Deferred tax charged to profit or loss and other comprehensive income	**9,247**	**14,473**
	iii. Synovia Pharma		
	Property, plant & equipment (difference in book value & tax base)	42,482	82,660
	Deferred liability (gratuity & pension)	(136,116)	(125,993)
	Provision for bad debts	(29,199)	(29,199)
	Carried forward loss	-	(138,050)
	Temporary difference	**(122,833)**	**(210,582)**
	Tax rate	27.5%	25.0%
	Deferred tax liability/(asset) at end of the period	(33,780)	(52,646)
	Deferred tax liability/(asset) at beginning of the period	(44,079)	(60,891)
	Deferred tax charged to profit or loss and other comprehensive income	**(10,299)**	**(8,245)**
		(16,863)	**3,243**

Taka '000

		For the period July 2025- March 2026	For the period July 2024- March 2025
16.	**Reconciliation of net profit with cash flows from operating activities**		
	Profit after tax	**7,048,632**	**5,261,007**
	Adjustment to reconcile net profit to net cash provided by operating activities		
	Non-cash/non-operating items	**1,549,842**	**1,467,348**
	Depreciation	1,297,966	1,311,807
	Amortization	282,606	194,002
	Deferred tax	16,863	(3,243)
	Exchange rate fluctuation (gain)/loss	(32,902)	(20,364)
	Dividend income	(1,256)	(1,142)
	(Profit)/loss on sale of fixed assets	(13,965)	(5,533)
	Effect of exchange rate changes on cash and cash equivalents	530	(8,179)
	Changes in working capital	**(1,132,416)**	**(2,507,523)**
	(Increase)/decrease in inventories	(639,186)	(1,982,109)
	(Increase)/decrease in spares and supplies	(166,837)	51,882
	(Increase)/decrease in trade and other receivables	(139,618)	(657,412)
	(Increase)/decrease in loans, advances, deposits and prepayments	(611,647)	(302,590)
	Increase/(decrease) in gratuity, pension & WPPF	261,601	316,471
	Increase/(decrease) in trade and other payables	(801,842)	(347,268)
	Increase/(decrease) in accrued expenses	255,644	154,771
	Increase/(decrease) in income tax payable	709,469	258,732
	Net cash generated from operating activities	**7,466,058**	**4,220,832**

17. Related party transaction

Name of related parties	Nature of transactions	Value of transaction	Balance at period end
I & I Services Limited	Delivery of products	37,160,072	1,116,226
	Distribution commission	1,020,220	

18. Significant events/deviations

The increase in net revenue compared with the corresponding prior period, together with improved gross margin, contributed positively to overall performance. Finance costs declined due to stronger cash inflows, while other income increased, primarily due to interest income generated from the short-term investment of surplus cash. As a result, earnings per share (EPS) recorded a notable improvement during the reporting period.

Additionally, reduced cash outflows associated with working capital supported an improvement in net operating cash flows per share.

Osman Kaiser Chowdhury	**Prof. Mamtaz Uddin Ahmed**	**Iqbal Ahmed**	**Mohammad Ali Nawaz**	**Mohammad Asad Ullah, FCS**
Director	Independent Director	Managing Director	Chief Financial Officer	Executive Director & Company Secretary

Beximco Pharmaceuticals PLC.

Financial Statements (Un-audited)

For the period July 2025-March 2026

Beximco Pharmaceuticals PLC.
Statement of financial position (Un-audited)
As at March 31, 2026

Taka '000

	Notes	March 31, 2026	June 30, 2025
ASSETS			
Non-current assets		**47,283,533**	**46,106,146**
Property, plant and equipment	3	38,429,843	37,311,514
Right-of-use assets		416,465	472,186
Intangible assets		1,475,103	1,360,324
Investment in subsidiaries	4a	6,911,822	6,911,822
Investment in associates		29,326	29,326
Other investments	4b	20,974	20,974
Current assets		**24,136,715**	**19,965,776**
Inventories	5	12,331,960	11,682,419
Spares and supplies		907,328	695,780
Trade and other receivables		3,752,662	3,647,140
Loans, advances, deposits and prepayments	6	3,008,667	2,415,994
Cash and cash equivalents	7	4,136,098	1,524,443
TOTAL ASSETS		**71,420,248**	**66,071,922**
EQUITY AND LIABILITIES			
Shareholders' equity		**58,977,925**	**52,320,598**
Share capital		4,461,121	4,461,121
Share premium		5,269,475	5,269,475
Excess of issue price over face value of GDRs		1,689,637	1,689,637
Capital reserve on merger		294,951	294,951
Revaluation surplus		1,102,935	1,105,222
Unrealized gain/(loss)		18,149	18,149
Retained earnings		46,141,657	39,482,043
Non-current liabilities		**7,390,927**	**7,355,686**
Long term borrowings-net of current maturity	8A	1,297,610	1,490,635
Liability for gratuity and WPPF		3,522,668	3,309,549
Deferred tax liability	14	2,570,649	2,555,502
Current liabilities		**5,051,396**	**6,395,638**
Short term borrowings		242,903	1,073,604
Long term borrowings-current maturity	8B	881,472	1,429,026
Trade and other payables		1,712,460	2,318,882
Accrued expenses		881,518	758,292
Dividend payable	9	136,788	301,233
Income tax payable		1,196,255	514,601
TOTAL LIABILITIES		**12,442,323**	**13,751,324**
TOTAL EQUITY AND LIABILITIES		**71,420,248**	**66,071,922**

Osman Kaiser Chowdhury	Prof. Mamtaz Uddin Ahmed	Iqbal Ahmed	Mohammad Ali Nawaz	Mohammad Asad Ullah, FCS
Director	Independent Director	Managing Director	Chief Financial Officer	Executive Director & Company Secretary

Beximco Pharmaceuticals PLC.
Statement of profit or loss and other comprehensive income (Un-audited)
For the period July 2025-March 2026

Taka '000

	Notes	July 2025-March 2026	July 2024-March 2025	January-March 2026	January-March 2025
Net revenue		**34,447,075**	**30,543,353**	**11,346,039**	**10,591,649**
Cost of goods sold	10	(17,685,068)	(16,576,555)	(5,771,724)	(5,699,621)
Gross profit		**16,762,007**	**13,966,798**	**5,574,315**	**4,892,028**
Operating expenses		**(8,416,420)**	**(7,257,582)**	**(2,947,828)**	**(2,722,307)**
General and administrative expenses	11	(887,386)	(802,877)	(313,047)	(285,095)
Selling, marketing and distribution expenses	12	(7,529,034)	(6,454,705)	(2,634,781)	(2,437,212)
Profit from operations		**8,345,587**	**6,709,216**	**2,626,487**	**2,169,721**
Other income	13	1,052,130	916,882	355,596	402,827
Finance cost		(440,074)	(756,508)	(118,382)	(293,048)
Profit before tax and WPPF		**8,957,643**	**6,869,590**	**2,863,701**	**2,279,500**
Contribution to WPPF		(426,554)	(327,123)	(136,366)	(108,547)
Profit before tax		**8,531,089**	**6,542,467**	**2,727,335**	**2,170,953**
Income tax expenses		**(1,874,426)**	**(1,419,681)**	**(585,286)**	**(469,106)**
Current tax		(1,858,615)	(1,416,696)	(576,076)	(465,411)
Deferred tax	14	(15,811)	(2,985)	(9,210)	(3,695)
Profit after tax		**6,656,663**	**5,122,786**	**2,142,049**	**1,701,847**
Other comprehensive income		-	1	-	-
Total comprehensive income		**6,656,663**	**5,122,787**	**2,142,049**	**1,701,847**
Earnings per share (EPS)		**14.92**	**11.48**	**4.80**	**3.81**
Number of shares		446,112,089	446,112,089	446,112,089	446,112,089

Osman Kaiser Chowdhury	**Prof. Mamtaz Uddin Ahmed**	**Iqbal Ahmed**	**Mohammad Ali Nawaz**	**Mohammad Asad Ullah, FCS**
Director	Independent Director	Managing Director	Chief Financial Officer	Executive Director & Company Secretary

Beximco Pharmaceuticals PLC.
Statement of changes in equity (Un-audited)
For the period July 2025-March 2026

For the period July 2025-March 2026 Taka '000

Particulars	Share capital	Share premium	Excess of issue price over face value of GDRs	Capital reserve on merger	Revaluation surplus	Unrealized gain/(loss)	Retained earnings	Total
Balance as on July 01, 2025	**4,461,121**	**5,269,475**	**1,689,637**	**294,951**	**1,105,222**	**18,149**	**39,482,043**	**52,320,598**
Total comprehensive income:								
Profit for the period	-	-	-	-	-	-	6,656,663	6,656,663
Others:								
Adjustment for depreciation on revalued assets	-	-	-	-	(2,951)	-	2,951	-
Adjustment for deferred tax on revalued assets	-	-	-	-	664	-	-	664
Balance as on March 31, 2026	**4,461,121**	**5,269,475**	**1,689,637**	**294,951**	**1,102,935**	**18,149**	**46,141,657**	**58,977,925**
Number of shares								446,112,089
Net asset value (NAV) per share							**Tk.**	**132.20**

For the period July 2024-March 2025

Particulars	Share capital	Share premium	Excess of issue price over face value of GDRs	Capital reserve on merger	Revaluation surplus	Unrealized gain/(loss)	Retained earnings	Total
Balance as on July 01, 2024	**4,461,121**	**5,269,475**	**1,689,637**	**294,951**	**1,108,658**	**18,148**	**34,549,495**	**47,391,485**
Total comprehensive income:								
Profit for the period	-	-	-	-	-	-	5,122,786	5,122,786
Other comprehensive income	-	-	-	-	-	1	-	1
Transactions with the shareholders:								
Cash dividend	-	-	-	-	-	-	(1,784,448)	(1,784,448)
Others:								
Adjustment for depreciation on revalued assets	-	-	-	-	(3,325)	-	3,325	-
Adjustment for deferred tax on revalued assets	-	-	-	-	748	-	-	748
Balance as on March 31, 2025	**4,461,121**	**5,269,475**	**1,689,637**	**294,951**	**1,106,081**	**18,149**	**37,891,158**	**50,730,572**
Number of shares								446,112,089
Net asset value (NAV) per share							**Tk.**	**113.72**

Osman Kaiser Chowdhury	Prof. Mamtaz Uddin Ahmed	Iqbal Ahmed	Mohammad Ali Nawaz	Mohammad Asad Ullah, FCS
Director	Independent Director	Managing Director	Chief Financial Officer	Executive Director & Company Secretary

Beximco Pharmaceuticals PLC.
Statement of cash flows (Un-audited)
For the period July 2025-March 2026

Taka '000

	Notes	July 2025-March 2026	July 2024-March 2025
Cash flows from operating activities			
Cash receipts from customers and others		35,171,101	30,551,824
Cash paid to suppliers and employees		(26,791,183)	(25,009,521)
Cash generated from operations		**8,379,918**	**5,542,303**
Interest paid		(452,631)	(722,148)
Interest received		58,789	238
Income tax paid		(1,176,961)	(1,162,979)
Net cash generated from operating activities	**15**	**6,809,115**	**3,657,414**
Cash flows from investing activities			
Acquisition of property, plant and equipment		(2,361,631)	(2,074,711)
Intangible assets		(279,255)	(161,633)
Disposal of property, plant and equipment		2,598	38,961
Disposal of intangible assets		18,255	-
Dividend received		125,932	120,742
Net cash used in investing activities		**(2,494,101)**	**(2,076,641)**
Cash flows from financing activities			
Net increase/(decrease) in long term borrowings		(707,677)	64,951
Net increase/(decrease) in short term borrowings		(830,701)	847,604
Dividend paid		(164,445)	(1,560,085)
Net cash from/(used in) financing activities		**(1,702,823)**	**(647,530)**
Increase/(decrease) in cash and cash equivalents		**2,612,191**	**933,243**
Opening cash and cash equivalents		1,524,443	757,080
Effect of exchange rate changes on cash and cash equivalents		(536)	8,143
Closing cash and cash equivalents	**7**	**4,136,098**	**1,698,466**

Net operating cash flows per share	**15.26**	**8.20**
Number of shares	446,112,089	446,112,089

Osman Kaiser Chowdhury	**Prof. Mamtaz Uddin Ahmed**	**Iqbal Ahmed**	**Mohammad Ali Nawaz**	**Mohammad Asad Ullah, FCS**
Director	Independent Director	Managing Director	Chief Financial Officer	Executive Director & Company Secretary

Beximco Pharmaceuticals PLC.
Selected notes to the financial statements (Un-audited)
For the period July 2025-March 2026

1. Reporting entity

1.1 About the Company

Beximco Pharmaceuticals PLC. (Beximco Pharma/BPP/the Company) is a public limited company incorporated in Bangladesh in 1976. It is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). Company's shares were first listed on the Dhaka Stock Exchange in 1985 and subsequently on the Chittagong Stock Exchange in 1995. In 2005, BPP acquired Beximco Infusions Ltd., a publicly listed company specializing in the production and marketing of intravenous fluids. To expand its global presence, BPP issued Global Depository Receipts (GDRs) and secured a listing on the Alternative Investment Market (AIM) of the London Stock Exchange. In 2018, BPP acquired 85.22% shares of Nuvista Pharma PLC. (Nuvista Pharma/NPP) – an unlisted pharmaceutical company in Bangladesh specializing in hormones and steroid drugs. In October 2021, BPP acquired majority stake (54.6%) in Sanofi Bangladesh Limited from Sanofi Group represented through May & Baker Limited and Fisons Limited. Sanofi Bangladesh Limited was subsequently renamed as Synovia Pharma PLC. (Synovia Pharma/SPP). Bangladesh Government holds 45.4% shares of the company represented through the Bangladesh Chemical Industries Corporation (20%) and the Ministry of Industries (25.4%). SPP, like Nuvista Pharma, is an unlisted pharmaceutical company operating in Bangladesh. Shares of Beximco Pharma are traded on the Dhaka and Chittagong Stock Exchanges within Bangladesh, while its GDRs are traded on the AIM of the London Stock Exchange.

The corporate headquarters of Beximco Pharma is based in Dhaka. The industrial units are located at Tongi and Kaliakoir of Gazipur district–vicinities close to the capital city Dhaka. The manufacturing facilities of the Company are certified by leading global regulatory authorities including United States Food and Drug Administration (USFDA).

1.2 Nature of business

The Company is engaged in manufacturing and marketing of generic pharmaceuticals formulation products across diverse spectrum of therapeutic areas. The product portfolio includes a variety of dosage forms such as solid, liquid, creams and ointments, suppositories, metered dose inhalers, dry powder inhalers, nasal sprays, sterile items, lyophilized injectables, and large volume intravenous fluids. Additionally, BPP is involved in the manufacturing of Active Pharmaceutical Ingredients (APIs) and extends contract manufacturing services to other companies. Products of the Company are sold in domestic and international markets.

2. Basis of preparation of financial statements

These interim financial statements should be read in conjunction with the financial statements for the year ended June 30, 2025 (hereafter referred to as the "Annual financial statements"), as they provide an update to previously reported information.

The accounting policies used are consistent with those used in the annual financial statements. These financial statements have been prepared in a condensed form with selected notes following IAS 34: Interim Financial Reporting. The presentation of the interim financial statements is consistent with the annual financial statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the annual financial statements. The preparation of the interim financial statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the interim financial statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

The financial statements are prepared and presented in Bangladesh currency (Taka), which is the Company's functional currency. All financial information presented has been rounded off to the nearest thousand Taka except where indicated otherwise.

Taka '000

		March 31, 2026	June 30, 2025
3.	**Property, plant and equipment**		
	Land	3,652,766	3,652,766
	Building and other constructions	15,666,987	15,626,539
	Plant and machinery	28,050,831	28,013,580
	Furniture and fixtures	887,480	845,301
	Transport and vehicle	1,105,901	1,011,227
	Office equipment	915,496	849,798
		50,279,461	**49,999,211**
	Less: Accumulated depreciation	(17,023,217)	(15,926,048)
	Net book value	**33,256,244**	**34,073,163**
	Capital work in progress	5,173,599	3,238,351
	Carrying value	**38,429,843**	**37,311,514**
4a.	**Investment in subsidiaries**		
	Nuvista Pharma PLC.	2,125,186	2,125,186
	Synovia Pharma PLC.	4,766,636	4,766,636
	Beximco Pharma API Limited	20,000	20,000
		6,911,822	**6,911,822**
4b.	**Other investments**		
	Bangladesh Export Import Company PLC.	19,405	19,405
	Central Depository Bangladesh Ltd. (CDBL)	1,569	1,569
		20,974	**20,974**
5.	**Inventories**		
	Finished goods	2,051,426	1,989,708
	Raw and packing materials (including work in process, laboratory chemicals, R&D materials and material in transit)	10,152,540	9,583,526
	Physician sample	127,994	109,185
		12,331,960	**11,682,419**
6.	**Loans, advances, deposits and prepayments**		
	Clearing and forwarding	188,882	130,685
	VAT	644,280	555,518
	Security deposit & earnest money	173,920	161,488
	Lease deposit	1,477	1,477
	Advance for expenses including capital expenditure	790,323	557,265
	Bank guarantee margin	54,792	26,215
	Advance against salary	68,514	86,914
	Vehicle advance	178,826	137,313
	Raw & packing material	366,284	381,576
	Overseas liaison office	47,812	43,366
	Others	493,557	334,177
		3,008,667	**2,415,994**

Taka '000

		March 31, 2026	June 30, 2025
7.	**Cash and cash equivalents**		
	a. Cash in hand (including imprest cash)	624,019	381,313
	b. Cash at bank		
	Current & FC account	3,512,079	1,143,130
		4,136,098	**1,524,443**
8.	**Long term borrowings**		
	A. Net of current maturity		
	Project loan-ODDO BHF SE, Frankfurt, Germany	1,089,951	1,202,080
	Lease liability	207,659	288,555
		1,297,610	**1,490,635**
	B. Current maturity		
	Project loan-ODDO BHF SE, Frankfurt, Germany	526,772	300,520
	Term loan-Agrani Bank PLC.	274,391	1,017,849
	Lease liability	80,309	110,657
		881,472	**1,429,026**

9. Dividend payable

The Dividend payable as on March 31, 2026 consists of Tk. 83,781K relating to year 2023-24 which has been paid but not yet claimed. The remaining balance relates to dividend for prior years unclaimed to date.

		For the period July 2025-March 2026	For the period July 2024-March 2025
10.	**Cost of goods sold**		
	Work-in-process (opening)	1,218,975	1,134,373
	Materials consumed	13,432,178	13,003,920
	Factory overhead	4,494,087	4,123,212
	Total manufacturing cost	**19,145,240**	**18,261,505**
	Work-in-process (closing)	(1,098,299)	(1,139,580)
	Cost of goods manufactured	**18,046,941**	**17,121,925**
	Finished goods (opening)	1,989,708	2,089,049
	Finished goods available	**20,036,649**	**19,210,974**
	Cost of physician sample transferred to sample stock	(300,155)	(275,290)
	Finished goods (closing)	(2,051,426)	(2,359,129)
		17,685,068	**16,576,555**
11.	**General and administrative expenses**		
	Salaries and allowances	439,445	375,930
	Repairs and maintenance	50,467	65,397
	Travelling and conveyance	33,530	29,915
	Company secretarial, regulatory fee and AGM expense	38,087	33,978
	Depreciation	75,512	25,049
	Security expenses	60,714	31,037
	Other expenses	189,631	241,571
		887,386	**802,877**

Taka '000

	For the period July 2025-March 2026	For the period July 2024-March 2025
12. Selling, marketing and distribution expenses		
Salaries and allowances	2,611,155	2,277,059
Travelling and conveyance	745,045	611,929
Market research and new products	43,181	38,468
Sample expense	421,561	375,879
Literature and newsletter	255,048	235,380
Events, programs and campaign	368,840	298,188
Brand development	204,561	155,379
Sales promotion expenses	184,170	154,093
Distribution commission	1,020,220	631,274
Delivery expense	478,505	472,507
Depreciation and amortization	218,705	173,427
Export insurance, freight and C&F expenses	118,878	228,556
Security expenses	34,945	32,301
Bad debts	14,129	5,671
Other expenses	810,091	764,594
	7,529,034	**6,454,705**
13. Other income		
Interest income	58,789	238
Distribution commission	413,588	344,749
Cash incentive on export	166,770	144,048
Dividend income	125,932	120,910
Royalty	248,591	223,036
Exchange rate fluctuation gain/(loss)	32,965	79,362
Profit/(loss) on sale of fixed assets	5,495	4,539
	1,052,130	**916,882**
14. Deferred tax		
Deferred tax is arrived at as follows :		
Property, plant & equipment (difference in book value & tax base)	13,460,630	13,182,005
Deferred liability (gratuity)	(1,836,470)	(1,872,784)
Lease liability-(office rent)	(165,909)	-
Provision for bad debts	(33,144)	(19,015)
Temporary difference	**11,425,107**	**11,290,206**
Tax rate	22.5%	22.5%
Deferred tax liability at end of the period	2,570,649	2,540,296
Deferred tax liability at beginning of the period	2,555,502	2,538,059
Change in deferred tax liability	**(15,147)**	**(2,237)**
Deferred tax on revaluation surplus	(664)	(748)
Deferred tax charged to profit or loss and other comprehensive income	**(15,811)**	**(2,985)**

Taka '000

	For the period July 2025- March 2026	For the period July 2024- March 2025
15. Reconciliation of net profit with cash flows from operating activities		
Profit after tax	**6,656,663**	**5,122,786**
Adjustment to reconcile net profit to net cash provided by operating activities		
Non-cash/non-operating items:	**1,178,437**	**1,110,118**
Depreciation	1,172,667	1,194,705
Amortization	153,752	66,348
Deferred tax	15,811	2,985
Exchange rate fluctuation (gain)/loss	(32,902)	(20,328)
Dividend income	(125,932)	(120,910)
(Profit)/loss on sale of fixed assets	(5,495)	(4,539)
Effect of exchange rate changes on cash and cash equivalents	536	(8,143)
Changes in working capital	**(1,025,985)**	**(2,575,490)**
(Increase)/decrease in inventories	(649,541)	(1,760,379)
(Increase)/decrease in spares and supplies	(211,548)	13,440
(Increase)/decrease in trade and other receivables	(105,522)	(754,256)
(Increase)/decrease in loans, advances, deposits and prepayments	(490,560)	(359,640)
Increase/(decrease) in gratuity & WPPF	213,119	255,482
Increase/(decrease) in trade and other payables	(586,813)	(379,563)
Increase/(decrease) in accrued expenses	123,226	155,709
Increase/(decrease) in income tax payable	681,654	253,717
Net cash generated from operating activities	**6,809,115**	**3,657,414**

16. Related party disclosures

Name of related parties	Nature of transactions	Value of transaction	Balance at period end	Balance type
a. I & I Services Limited	Delivery of products	37,160,072	1,116,226	Dr.
	Distribution commission	1,020,220		
b. Nuvista Pharma PLC.	Toll manufacturing expenses	31,547	41,819	Dr.
	Materials procurement	110,536		
	Other goods & services	64,647		
	Royalty	32,628		
	Distribution commission	208,103		
	Dividend	100,135		
c. Synovia Pharma PLC.	Toll manufacturing expenses	314,380	178,112	Dr.
	Materials procurement	272,402		
	Other goods & services	100,218		
	Royalty	15,000		
	Distribution commission	205,485		
	Dividend	24,541		
d. Beximco Pharma API Limited	Short term advance	50	1,096	Dr.

17. Significant events/deviations

The increase in net revenue compared with the corresponding prior period, together with improved gross margin, contributed positively to overall performance. Finance costs declined due to stronger cash inflows, while other income increased. As a result, earnings per share (EPS) recorded a notable improvement during the reporting period.

Additionally, reduced cash outflows associated with working capital supported an improvement in net operating cash flows per share.

Osman Kaiser Chowdhury	**Prof. Mamtaz Uddin Ahmed**	**Iqbal Ahmed**	**Mohammad Ali Nawaz**	**Mohammad Asad Ullah, FCS**
Director	Independent Director	Managing Director	Chief Financial Officer	Executive Director & Company Secretary